Winrevair is now FDA-approved to treat pulmonary arterial hypertension to improve exercise capacity and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death.
Winrevair is now FDA-approved to treat pulmonary arterial hypertension to improve exercise capacity and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death.
Read More
Results from a Phase 3 clinical study of adults with pulmonary arterial hypertension found Winrevair reduced the risk of clinical worsening events by 76%.
Read More
As a subcutaneous injection, Keytruda Qlex may provide added convenience compared to IV Keytruda because it can be administered by HCPs in multiple settings.
Read More
Merck will acquire Verona Pharma’s FDA-approved ensifentrine/Ohtuvayre for the maintenance treatment of COPD in adult patients.
Read More
After receiving FDA approval earlier this month, Merck’s Enflonsia was recommended by the CDC’s ACIP for the prevention of RSV lower respiratory tract disease in infants under 8 months entering their first RSV season.
Read More
The FDA approved Enflonsia, a long-acting monoclonal antibody designed to protect neonates and infants from RSV-related lower respiratory tract disease.
Read More
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Read More
The phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Read More
The trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
Read More
The inhaled therapy for the maintenance treatment of COPD combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule.
Read More
A new RNA-based vaccine approved by the USDA offers protection against the year-round threat of canine influenza.
Read More
The vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older.
Read More
The injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
Read More
The FDA accepted for priority review a new Biologics License Application for V116, Merck’s investigational 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
Read More
Researchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read More
The FDA approved an expanded indication for Merck’s Ervebo vaccine, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
Read More
Merck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read MoreWith these approvals, healthcare professionals now have the option to administer Merck’s measles, mumps, rubella, and varicella vaccines intramuscularly.
Read More
The US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read More
The FDA has expanded the approval for Merck’s Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Read More
The FDA issued emergency authorization for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults age 18 and older with positive results of direct SARS-CoV-2 viral testing.
Read More
The European Commission approved Merck’s VaxNeuvance (Pneumococcal 15-valent Conjugate Vaccine) for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Read More
Experts say the success of COVID Antiviral Pills depends on whether high-risk patients will be able to get tested, and then treated, fast enough to make a difference.
Read More
Merck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Read More
